Japan Oral Anti-Diabetic Drug Market Report - Table of Contents

1. INTRODUCTION

1.1 Study Assumptions And Market Definition

1.2 Scope Of The Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Growth in Diabetes Population in Japan is Driving the Mark

4.2.2 Reimbursement Policies For Diabetes Oral Medications

4.3 Market Restraints

4.3.1 Stringent Regulatory Requirements For Product Approval May Impede the Growth of the Market

4.4 Porter's Five Forces Analysis

4.4.1 Bargaining Power of Suppliers

4.4.2 Bargaining Power of Consumers

4.4.3 Threat of New Entrants

4.4.4 Threat of Substitute Products and Services

4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

5.1 By Drug Type

5.1.1 Biguanides

5.1.2 Alpha-Glucosidase Inhibitors

5.1.3 GLP-1 Receptor Agonists

5.1.4 SGLT-2 Inhibitors

5.1.5 DPP-4 Inhibitors

5.1.6 Others

5.2 By End Users

5.2.1 Hospitals/Clinics

5.2.2 Personal/Home Care Settings

5.2.3 Others

6. MARKET INDICATORS

1. 6.1 Type-1 Diabetic Population (2024 - 2023)
2. 6.2 Type-2 Diabetic Population (2024 - 2023)

7. COMPETITIVE LANDSCAPE

7.1 COMPANY PROFILES

7.1.1 Takeda Pharmaceutical Company Limited

7.1.2 Novo Nordisk A/S

7.1.3 Pfizer Inc.

7.1.4 Eli Lilly and Company

7.1.5 Johnson And Johnson

7.1.6 Astellas Pharma Inc.

7.1.7 Boehringer Ingelheim International GmbH

7.1.8 Merck And Co., Inc.,

7.1.9 AstraZeneca

7.1.10 Bristol-Myers Squibb Company

7.1.11 Novartis AG

7.1.12 Sanofi

8. MARKET OPPORTUNITIES AND FUTURE TRENDS